Web Watch

Web Watch in One Page

The verdict on Tenet is "Lean Long, Wait For Confirmation," and the gap between the $135 bear scenario and the $245 bull scenario runs through evidence that should land inside two earnings cycles. These five live watches map to the report's most important open questions: whether OBBBA Medicaid implementation rules in H2 2026 lock in a $300–500M FY2027 hospital EBITDA hit; whether the SEC enforcement matter flagged by the Fuzzy Panda FOIA 7(A) appeal turns into charges, settlement, or quiet closure; whether the next two earnings prints show USPI same-facility ≥5% with hospital margin defended; whether Optum/SCA Health uses UnitedHealth payer leverage to steer commercial volume out of USPI ASCs; and whether Conifer announces a real 2027 client backfill before the CommonSpirit revenue base disappears on December 31, 2026. Each watch is built around what would actually be a new, material event for the investment view rather than generic news flow.

Active Monitors

Rank	Watch item	Cadence	Why it matters	What would be detected
1	OBBBA Medicaid rules & CMS site-neutral / OPPS-ASC payment policy	1d	The single biggest 2027 binary. Hospital Operations is 76% of revenue and 56% of EBITDA; bear-sized $300–500M annual hit if state-directed payment caps bind in non-expansion states (FL, SC, TN, TX, where 50%+ of beds sit). Site-neutral and IPO-list policy also drive USPI's structural tailwind.	Federal Register notices, CMS/Treasury implementation rules, proposed/final OPPS-ASC rules, site-neutral expansion language, and hospital-industry guidance on compliance scope.
2	SEC enforcement matter, restatement risk, and Wells notices	1d	Independent re-rate event. Fuzzy Panda Research alleged $675–845M Medicare/Medicaid fines and confirmed an SEC FOIA 7(A) exemption response consistent with an active investigation. PAO transition effective May 1, 2026 is the textbook moment for deferred adjustments to surface.	Tenet 8-K filings disclosing Wells notices, settlements, restatements, or accounting estimate changes; SEC litigation releases naming Tenet; follow-up short reports; DOJ FCA actions.
3	Tenet quarterly results, USPI same-facility prints, and FY guide revisions	1d	The decisive variable both bull and bear named: USPI same-facility growth ≥5% for two prints validates the SOTP rerate; sub-5% breaks it. Hospital RPAA, SWB ratio, FY2026 guide direction, and any first 2027 commentary are all in the same release. Q2 earnings ~late July and Q3 ~late October.	Press releases or webcast transcripts disclosing segment EBITDA, USPI same-facility revenue, hospital RPAA/admissions, SWB%, FY2026 guidance changes, and any directional FY2027 commentary or buyback authorization changes.
4	UnitedHealth / Optum / SCA Health competitive pressure on USPI	1d	Bull SOTP requires USPI to earn a SGRY-comparable multiple. UnitedHealth controls the largest commercial payer and the second-largest national ASC platform (SCA Health, ~280 facilities) — narrow-network design or selective steerage starting 2026–2027 would directly compress USPI same-facility growth and the moat thesis. The risk is currently absent from sell-side models.	New SCA Health acquisitions, narrow-network announcements from UnitedHealthcare/Optum that exclude USPI ASCs, payer-driven network redesigns favoring SCA, contract disputes between Tenet/USPI and UnitedHealth, or DOJ/FTC commentary on UnitedHealth vertical integration.
5	Conifer post-CommonSpirit RCM client backfill	1w	CommonSpirit accounts for ~44% of Conifer revenue and services wind down December 31, 2026. Without disclosed wins, 2027 Conifer EBITDA likely halves from ~$200M to ~$100M and the $1.9B contract-buyout cash starts to look like a one-time inflation of FCF. A material new health-system RCM contract would partially refute the bear-side FCF-quality concern.	New large-client RCM contract announcements, health-system selection of Conifer for revenue-cycle outsourcing, public 2027 Conifer revenue/EBITDA guidance, or competitor (R1, Ensemble) announcements winning Tenet-adjacent business.

Why These Five

The report's verdict is explicit that the path runs through two unresolved swing factors — USPI same-facility growth and the SEC enforcement matter — and that the FY2027 EPS line frozen flat by sell-side hinges on a single regulatory binary, OBBBA implementation. Monitors 1, 2, and 3 cover those three signals directly. Monitor 4 watches the only competitor named in the moat tab as capable of breaking USPI inside 24 months, a risk the report flagged as not yet priced in. Monitor 5 closes the loop on the forensic concern that headline FCF is inflated by the one-time $1.9B Conifer contract buyout — the new-client question is what would convert that "accretion" back into durable earnings. Everything else (insider activity, payer disputes, conference cadence, quality-of-care issues) the report flagged as noise unless one of these five surfaces it.